Nycomed's Instanyl® is first intranasal fentanyl approved in Europe
Nycomed announced that the European Commission has granted marketing authorisation for Instanyl®, its first-in-class intranasal fentanyl spray. Instanyl is aimed at managing breakthrough pain in adult cancer patients already receiving maintenance opioid therapy for chronic pain.
Read more ...
MabThera receives positive opinion in Europe for treating patients whose chronic lymphocytic leukaemia returns
Roche announced that the European Union's Committee on Human Medicinal Products (CHMP) has issued a positive recommendation for the use of MabThera (rituximab) in patients with relapsed or refractory chronic lymphocytic leukaemia (CLL).
Read more ...
Merck KGaA Submits Application for Cladribine Tablets as Multiple Sclerosis Therapy in Europe
Merck KGaA announced today the submission of a marketing authorization application (MAA) to the European Medicines Agency (EMEA) for Cladribine Tablets, Merck’s proprietary investigational oral formulation of cladribine, as a therapy for patients with relapsing-remitting multiple sclerosis (MS).
Read more ...
Pfizer Reports Second-Quarter 2009 Revenues of $11.0 Billion
Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2009. Revenues were $11.0 billion, a decrease of 9% compared with the year-ago quarter and flat on a constant currency basis. Foreign exchange unfavorably impacted revenues by approximately $1.1 billion or 9%. For second-quarter 2009, U.S. revenues were $4.5 billion, a decrease of 5% compared with the year-ago quarter.
Read more ...
Xeloda in combination with oxaliplatin shown to be effective in early colon cancer
Roche has announced results from the international phase III study NO16968 (XELOXA), investigating oral Xeloda in combination with intravenous oxaliplatin (XELOX) immediately after surgery, which show that patients with colon cancer taking XELOX live disease free for longer compared to those taking the commonly used intravenous chemotherapy combination 5-fluorouracil/leucovorin (5-FU/LV). The data prove that XELOX is superior to 5-FU/LV in terms of the time patients live without their cancer being detectable.
Read more ...
Novartis delivers strong operational performance in the first half of 2009
Pharmaceuticals an industry growth leader: Net sales up 12% (local currencies) in first half of 2009 on contributions from new products and expansion in all regions
R&D maintains momentum: Anti-cancer therapy Afinitor introduced in the US, awaiting EU approval; new biologic Ilaris and OTC brand Prevacid 24HR gain US approvals; clinical trials set to start in July for A(H1N1) pandemic flu vaccine
H1 2009 operating results advance well, but impacted negatively by currencies:
Read more ...
Pfizer Receives Approval From European Commission For Pending Acquisition Of Wyeth
Pfizer Inc (NYSE: PFE) today announced that the European Commission (EC) has approved under the European Union (EU) Merger Regulation the company's pending acquisition of Wyeth. The Commission's decision includes Pfizer's commitment to divest certain animal health assets in the EU.
Read more ...